Screen for 50+ cancers with a single blood test

The Galleri® multi-cancer early detection test screens for many aggressive cancer that lack recommended screening in early stages before symptoms appear.1,2

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening test. 

2024 compilation

Who is the Galleri test for?

The Galleri test is recommended for adults with an elevated risk for cancer, such as those ages 50 or older.

  • The Galleri test is available by prescription only.
  • Use of the Galleri test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Age is the biggest risk factor for cancer. Adults over 50 are 13 times more likely to have  cancer compared to people under the age of 50.3

Certain factors, in addition to age 50+, further increase cancer risk4:

  • Diabetes
  • Obesity (BMI ≥ 30)
  • Current or previous smokers

Screen for more

Only 5 cancers have a recommended screening test: breast, cervical, colorectal, lung (for those at risk), and prostate.5 

Galleri5cancers

Adding the Galleri test to your annual cancer screenings can increase your chance of finding cancer early, when more treatment options may be available.5,6,7 In a clinical study, adding the Galleri test to recommended screenings led to 3 times as many cancers detected.8* 

The Galleri test should be used in addition to healthcare provider recommended screening tests.

*USPSTF A, B, and C rating, based on the first ~25,000 participants with 1 year of follow-up.

Testing process

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

The Galleri test is available by prescription only. You can request the test through our website from an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the independent telemedicine physician confirms you are eligible and orders your test, you can schedule a blood draw at one of GRAIL’s blood draw partners and we will ship you a Galleri collection kit for your appointment.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

The trained technician that draws your blood sample will ship the kit back to the GRAIL lab.
Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

An independent telemedicine provider will reach out when your results are ready — about 2 weeks after your blood draw. Your test result will be shared with you by an independent telemedicine provider.

What the Galleri test screens for

Evaluated in a large clinical study, the Galleri test screened for a signal shared by 50+ types of cancer.2

A

  • Adrenal Cortical Carcinoma
  • Ampulla of Vater
  • Anus
  • Appendix, Carcinoma

B

  • Bile Ducts, Distal
  • Bile Ducts, Intrahepatic
  • Bile Ducts, Perihilar
  • Bladder, Urinary
  • Bone
  • Breast

C

  • Cervix
  • Colon and Rectum

E

  • Esophagus and Esophagogastric Junction

G

  • Gallbladder
  • Gastrointestinal Stromal Tumor
  • Gestational Trophoblastic Neoplasms

K

  • Kidney

L

  • Larynx
  • Leukemia
  • Liver
  • Lung
  • Lymphoma (Hodgkin and Non-Hodgkin)

M

  • Melanoma of the Skin
  • Merkel Cell Carcinoma
  • Mesothelioma, Malignant Pleural

N

  • Nasal Cavity and Paranasal Sinuses Nasopharynx
  • Neuroendocrine Tumors of the Appendix
  • Neuroendocrine Tumors of the Colon and Rectum
  • Neuroendocrine Tumors of the Pancreas

O

  • Oral Cavity
  • Oropharynx (HPV-Mediated, p16+)
  • Oropharynx (p16-) and Hypopharynx
  • Ovary, Fallopian Tube and Primary Peritoneum

P

  • Pancreas, exocrine
  • Penis
  • Plasma Cell Myeloma and Plasma Cell Disorders
  • Prostate

S

  • Small Intestine
  • Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs
  • Soft Tissue Sarcoma of the Head and Neck
  • Soft Tissue Sarcoma of the Retroperitoneum
  • Soft Tissue Sarcoma of the Trunk and Extremities
  • Soft Tissue Sarcoma Unusual Histologies and Sites
  • Stomach

T

  • Testis

U

  • Ureter, Renal Pelvis
  • Uterus, Carcinoma and Carcinosarcoma
  • Uterus, Sarcoma

V

  • Vagina
  • Vulva

What do Galleri test results mean?


The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 tests has a Cancer Signal Detected result.7

This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a Cancer Signal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,9

In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.8*

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imaging ordered by your healthcare provider to confirm cancer.

The cost of the Galleri test does not include additional diagnostic testing to confirm cancer. If you have questions about obtaining insurance coverage for diagnostic tests, please contact the GRAIL patient advocate, patient-advocate@grailbio.com for assistance.

*Based on the first ~25,000 participants with 1 year of follow-up.

The Galleri test did not detect DNA fragments associated with cancer in your blood sample.

Nearly 99% of people who use the Galleri test will screen negative.7

This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).10 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future.

Cancer signal not detected thumb

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur as this could lead to a delayed diagnosis.

Cancer can be unpredictable. The Galleri test can be taken as a simple annual blood test. Adding the Galleri test to annual wellness visits can improve your chance of finding cancer early.11 Ask your healthcare provider when it is best to test again.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

The Galleri test should be used in addition to healthcare provider recommended screening tests.

FAQs

When you’re ready to take the Galleri test, you can schedule your blood draw at a time and place convenient for you:

  • One of our partner labs
  • Your home, office, or any preferred location by a trained technician

Watch the Clinical Laboratory Virtual Tour video to learn more about how your sample is processed at the GRAIL lab. 

First, do not break the quality seal on your sample collection kit. The kit should be opened by the trained technician who draws your blood sample. Make sure you store it at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, avoid storing your collection kit in the trunk of your car for long periods of time.

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing.

No fasting is required for the Galleri test.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes is typically drawn from a vein in your arm.

If you no longer wish to receive your Galleri test result, please contact your healthcare provider to request a cancellation. If you are not able to reach your healthcare provider or require further assistance, contact GRAIL Customer Service by completing the online form on the Contact Us web page or by calling (833) 694‑2553.

If your test has already been processed by the GRAIL laboratory you will be responsible for the cost of the test.

Typically, you can expect to receive your test result about 2 weeks after your sample arrives at the GRAIL lab. In certain cases, results may take up to 4 weeks. 

If you have not received your result within 2 weeks, GRAIL will notify you via email (sent to your email address if one was provided on your Test Requisition Form). 

It is important to understand that the timing of your test result does not indicate or predict the outcome of the test, nor does it impact the accuracy of the final result.

If you provide your email when ordering the test, your result will be emailed to you. You can also request your test result by contacting GRAIL Customer Service via the Contact Us online form or by calling (833) 694‑2553.

The Galleri test detected DNA methylation patterns often associated with cancer in your blood sample. About 1 out of every 100 tests has a Cancer Signal Detected result.1

This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a Cancer Signal Origin (CSO). The CSO helps your doctor determine the next steps for diagnosis.2

A healthcare provider should interpret the results. The test result is not a cancer diagnosis and requires follow-up diagnostic testing, which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide the next steps.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

 The Galleri test did not detect DNA methylation patterns associated with cancer in your blood sample. Nearly 99% of people who use the Galleri test will receive a No Cancer Signal Detected result.1

This result does not completely rule out the possibility of cancer, and you should continue with other cancer screenings your provider recommends. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, which makes them unlikely to be detected through a blood test (e.g., brain, skin, and early breast and prostate cancers).12 False positive and false negative results do occur. The Galleri test identifies DNA in the bloodstream shed by cancer cells and does not predict future genetic risk for cancer.

The Galleri test can be taken as an annual blood test. Adding the Galleri test to yearly wellness visits can improve your chance of finding a cancer signal early, when more treatment options may be available.1,6,12,13 Ask your healthcare provider when it is best to test again.

The Galleri test is intended to be used in addition to — and not replace — other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early. Adding the Galleri test to annual wellness visits can improve your chance of finding a cancer signal early when more treatment options may be available.13

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing to confirm cancer. Follow-up diagnostics may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide the next steps.

Cancer can be unpredictable. The Galleri test can be taken annually and added to your yearly wellness visits. Aggressive cancers can develop and progress quickly, sometimes in less than a year.12,13 Ask your healthcare provider when would be the best time to schedule your next test.

All results are automatically shared with the provider who ordered the test. If you would like us to fax your result to an additional healthcare provider, contact GRAIL Customer Service and complete the online form on the Contact Us web page or call (833) 694‑2553 to receive instructions on how to complete a results release form.

An earlier version of the Galleri test included either one (in most cases) or two Cancer Signal Origins with a Cancer Signal Detected result. The current version of the Galleri test includes one Cancer Signal Origin with a Cancer Signal Detected result. This change helps guide diagnostic follow-ups and is based on ongoing improvements in our science and data. The improved accuracy is 93.4%7 of the Cancer Signal Origin that predicts the tissue type or organ associated with the cancer signal.

  1. American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021- 0065] 
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  3. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. [Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.] 
  4. American Association for Cancer Research. Cancer progress report 2023.  https://cancerprogressreport.aacr.org/progress/
  5. US Preventive Services Task Force. A, B, and C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results 
  6. Hackshaw A, Cohen SS, Reichert H, et al. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer. 2021 Nov;125 (10): 1432-42. doi: 10.1038/s41416-021-01498-4 
  7. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
  8. Nabavizadeh N, McDonnell C, Kurbegov D, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER 2 study [presentation]. European Society for Medical Oncology (ESMO) Congress; 2025 Oct 17-21; Berlin. https://assets.grail.com/wp-content/uploads/2025/10/ESMO-2025_PF2-Initial-Results_Presentation_FINAL-CLEAN-10.16.2025.pdf
  9. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
  10. Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multicancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022;192(10):1368-78. doi: 10.1016/j.ajpath.2022.07.007 
  11. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality [poster]. European Society for Medical Oncology (ESMO) Virtual Congress; 2021 Sep 16-21